Curated news and analysis on clinical trials, drug approvals, and medical research.
Moderna's stock shows mixed signals with recent gains offset by multi-year declines. Valuation models suggest shares may be overvalued on some metrics while analysts maintain Hold ratings with downside price targets.
Novartis AG provides a sustainable dividend yield near 3%, supported by a ChartMill Dividend Rating of 7/10, exceptional profitability metrics including 33% operating margins, and a solid financial foundation with manageable payout ratios.
Meta-analysis of 23 trials finds neoadjuvant chemoimmunotherapy achieved 66% major pathologic response in head and neck cancer patients compared to 18% for dual-agent and 6% for single-agent immunotherapy, though survival impact remains unclear.
The FDA launched the Adverse Event Monitoring System (AEMS), consolidating seven legacy databases into a single platform with real-time reporting. The system is expected to save $120 million over five years while improving public access to safety data.
Two recent clinical trials found that adding immunotherapy to standard chemoradiation did not improve survival for patients with limited-stage small-cell lung cancer or high-risk HPV-positive oropharyngeal cancer, though both studies revealed important insights about treatment delivery and radiation scheduling.
Zydus Lifesciences launched ANYRA, India's first indigenously developed aflibercept biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer for multiple ophthalmic indications.
Bunnie Xo, wife of country star Jelly Roll, revealed she experienced suicidal thoughts while taking semaglutide, describing December 2025 as "one of the darkest times of my life." She emphasized the importance of discussing mental health side effects of weight-loss medications and encouraged others facing similar struggles to seek help.
Real-world data from over 300 large B-cell lymphoma patients treated with axicabtagene ciloleucel show response rates and survival outcomes remarkably similar to pivotal trial results, with 86% overall response rate and 74% one-year survival.
British Columbia recorded 1,826 unregulated drug toxicity deaths in 2025, a 21% decrease from 2024. New research links the decline to decreasing fentanyl concentrations in the illicit drug supply, though nearly five people continue to die daily.
Recent studies examine self-management strategies for breast cancer treatment-related cardiotoxicity and highlight risks of vertebral fractures after discontinuing denosumab therapy in patients receiving aromatase inhibitors.
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
The World Health Organization published blueprints for urgently needed antibiotics targeting drug-resistant infections, while CARB-X awarded $1.2 million for novel antibiotic research and the FDA issued guidance on antibiotic duration limits in livestock.
The blood-brain barrier continues to block most treatments for glioblastoma and central nervous system diseases, with only 0.01% of biologic drugs reaching the brain. New intellectual property coverage and synthetic methods aim to address delivery challenges.
Recent studies demonstrate that blood-based biomarkers combined with AI can predict dementia risk 25 years early in women, identify liver cancer-prone environments with 93% accuracy, and classify prediabetes risk groups with 90% accuracy.
Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.
New market research reports analyze biotechnology collaboration agreements from 2020-2026, gas chromatography market growth projections, and Western blotting market trends through 2035.
Recent studies reveal immunotherapy failed to improve survival in small-cell lung cancer when combined with chemoradiation, while timing of immunotherapy after radiation therapy affects outcomes in non-small cell lung cancer patients.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
MajesTEC-9 trial demonstrates teclistamab's superiority over standard care in second-line multiple myeloma treatment, with significant progression-free survival and overall survival benefits supporting earlier use of the BCMA-targeting bispecific antibody.
Multiple institutional investors modified their Moderna Inc positions during recent quarters, with some funds increasing stakes while others reduced or exited positions, according to 13F filings.
